<DOC>
	<DOCNO>NCT00005674</DOCNO>
	<brief_summary>The purpose study evaluate safety effectiveness creatine treatment amyotrophic lateral sclerosis ( ALS ) . There currently know effective treatment ALS . It know nerve cell die brain spinal cord patient ALS cause cell death unknown . It show overactive nerve activity due increase level chemical call glutamate abnormal cellular metabolism along increase production substance call `` free radical . '' Improving cellular metabolism readjust activity glutamate brain may beneficial ALS patient . Creatine naturally occur compound , improve energy metabolism cell . Creatine give patient energy metabolism defect muscle , athlete . Creatine improve survival mouse model ALS . Three human subject ALS receive creatine six month without side effect . Overall , creatine well tolerate safe .</brief_summary>
	<brief_title>Clinical Trial Creatine Amyotrophic Lateral Sclerosis ALS</brief_title>
	<detailed_description>Half subject study select chance receive creatine treatment 6 month half receive placebo . Neither subject investigator know drug subject receiving , although information available case emergency . It anticipate subject choice receive creatine 6 month study open-label study additional 12 month . A total 114 patient participate 15 center . Approximately 8 subject enrol Washington University . The effectiveness creatine determine first assessing change strength arm second change grip strength , functional activity , electromyography change change level SOH 2'dG urine .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>A clinical diagnosis definite , probably laboratory support probably ALS , either sporadic familial ALS accord modify El Escorial criterion Willing able give inform consent FVC great equal 50 % predict Evidence abnormality upper and/or lower extremity motor function ( clinical evidence muscle atrophy weakness upper and/or low extremity ) . The patient least 4 8 testable upper extremity muscle group . Subjects may take riluzole . Riluzole must stable dos least thirty day prior baseline visit . If woman childbearing age , must nonlactating surgically sterile use effective method birth control ( double barrier oral contraceptive ) negative pregnancy test Disease duration less five year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2003</verification_date>
</DOC>